
SKIN Stock Forecast & Price Target
SKIN Analyst Ratings
Bulls say
Beauty Health's financial performance in the fourth quarter of 2023 showcased a revenue achievement of $96.8 million, surpassing both previous estimates and market expectations. This growth was primarily propelled by an increase in consumables, while the average selling price of their systems rose approximately 20% quarter-over-quarter to $28.8K, exceeding earlier projections. Additionally, the notable shift towards a higher percentage of direct sales positively impacted the overall revenue metrics, reflecting a strong demand for the company's innovative aesthetic technologies and products.
Bears say
The Beauty Health Company reported a significant decline in new core delivery system placements, with a drop of over 30% year-over-year and quarter-over-quarter to just 1,210 units, which is concerning as these placements are critical for driving future consumables sales necessary for profitability. Management's guidance for Q1 2024 indicates anticipated sales of $80 million and an adjusted EBITDA loss of approximately $7.5 million, which falls substantially short of previous estimates and raises concerns about the company's ability to reach positive EBITDA targets of $40 million for the full year. Furthermore, risks associated with brand integrity, macroeconomic challenges, a weaker upgrade cycle for the Syndeo device, and competition may hinder the company's growth prospects and overall market performance.
This aggregate rating is based on analysts' research of The Beauty Health Company and is not a guaranteed prediction by Public.com or investment advice.
SKIN Analyst Forecast & Price Prediction
Start investing in SKIN
Order type
Buy in
Order amount
Est. shares
0 shares